Becton Dickinson stock analysis
Becton Dickinson (BOX) Stock Price & Analysis
BOX Stock Chart & Stats
- Day’s Range
- CHF 236.53 - CHF 237.01
- 52-Week Range
- CHF 236.53 - CHF 237.01
- Previous Close
- CHF 236.53
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- CHF 47.30B
- Enterprise Value
- CHF 64.38B
- Total Cash (Recent Filing)
- CHF 733.00M
- Total Debt (Recent Filing)
- CHF 14.37B
- Price to Earnings (P/E)
- 51.9
- Beta
- N/A
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- 1.95
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.21%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Workflow Integration
BD's recurring consumables and embedded clinical workflows can support repeat purchasing across hospitals, laboratories, and pharmaceutical customers. Standardization and switching costs reinforce customer retention, while instrument-linked reagents and services broaden the recurring revenue base over the next several quarters.
Strong Cash Generation And Deleveraging
Rapid free-cash-flow growth gives BD flexibility to fund innovation, repay debt, return capital, and pursue focused acquisitions. The concurrent debt reduction strengthens financial resilience and can support sustained investment without relying as heavily on external financing.
Broad-based Platform Growth And Innovation
Growth across multiple platforms reduces reliance on a single product category and demonstrates traction in monitoring, pharmacy automation, biologic delivery, and specialty care. Continued share gains and accretive margins provide a durable foundation for portfolio growth and operating leverage.
Bears Say
Weak Recent Revenue And Profitability
Recent revenue contraction and weaker net-margin conversion indicate that stable gross and EBITDA margins have not fully translated into bottom-line performance. Lower ROE also signals reduced earnings power relative to the equity base, limiting near-term returns from the business.
Moderate Fiscal 2027 Growth Outlook
Low-single-digit growth and broadly flat operating margins imply limited near-term operating leverage after the portfolio transformation. Inflation, strategic investment, currency, and the Alaris comparison could constrain earnings progression even if underlying demand remains stable.
Alaris Comparison Creates Earnings Pressure
The Alaris comparison creates a material year-over-year hurdle, especially early in fiscal 2027, making reported growth and earnings progression look weaker despite underlying platform momentum. This burden can delay margin expansion and complicate execution assessment over coming quarters.
BOX FAQ
What was Becton Dickinson’s price range in the past 12 months?
What is Becton Dickinson’s market cap?
When is Becton Dickinson’s upcoming earnings report date?
How were Becton Dickinson’s earnings last quarter?
Is Becton Dickinson overvalued?
Does Becton Dickinson pay dividends?
What is Becton Dickinson’s EPS estimate?
How many shares outstanding does Becton Dickinson have?
What happened to Becton Dickinson’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Becton Dickinson?
What is the TipRanks Smart Score and how is it calculated?
Becton Dickinson Stock Smart Score
Company Description
Becton Dickinson
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Thomas E. Polen Jr.
- Employees
- 60,000
- Website
- www.bd.com
- Address
- 1 Becton Drive, Franklin Lakes, NJ, 07417-1880, US
Becton Dickinson (BOX) Earnings & Revenues
BOX Company Deck
BOX Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by strong Q4 revenue and adjusted EPS growth, broad-based momentum across key platforms, share gains, improved cash flow, productivity gains, innovation progress, and a completed portfolio transformation. The main challenges were the Alaris comparison, low-single-digit fiscal 2027 revenue guidance, flat reported operating margins, inflation and tariff effects, and the Q4 vaccine decline, but management characterized several of these pressures as temporary or moderating and expressed confidence in continued growth and margin expansion beyond fiscal 2027.
View all CH:BOX earnings summariesBOX Net sales Breakdown
- 52.45% Medical
- 23.66% Life Sciences
- 23.89% Interventional
BOX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 4 |
| Technical Analysis | 2 | 0 | 0 |
| Moving Averages | 2 | 6 | 4 |
